PA-BOOMI
19.7.2022 15:22:11 CEST | Business Wire | Press release
Boomi TM , the intelligent connectivity and automation leader, today claims two awards from Comparably , a leading workplace culture and corporate brand reputation platform, in their largest company category along with other 2022 honorees such as Microsoft, Adobe, IBM, Uber, and SADA. Honored with the Best CEOs for Diversity and Best Company for Career Growth awards – based on anonymous employee feedback from its more than 1,700 global employees – Boomi ranks among the top 50 largest companies for its commitments to, and achievements in, diversity and career advancement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005282/en/
“At Comparably we reward transparency in the workplace,” said Jason Nazar, co-founder and CEO at Comparably. “These awards empower employees to share personal insights about their company’s culture, rewarding and highlighting companies like Boomi, that do great work and set up their employees for success.”
Comparably selected the winners by evaluating over 15 million anonymous employee ratings across 70,000 of the largest companies. Boomi employees ranked their professional development opportunities, such as meaningful career advancement, mentorship, and valuable feedback, as high, which led to Boomi’s recognition among Best Companies for Career Growth. In awarding Best CEOs for Diversity to Boomi, Comparably evaluated ratings of Meredith from Boomi’s employees of color. The 2022 award for Meredith marks his second consecutive year receiving this important designation.
“As a category-leading, high growth, global software as a service (SaaS) company, Boomi strives to create and maintain a world-class employee experience,” said Shawn Maurice, Chief Human Resources Officer at Boomi. “We live by our motto of ‘hiring good humans’ and our unique, core values of Go Beyond, Play for Each Other, Create Awesome Things, Own It, and Build Trust. Boomi’s success ultimately lies in the hands of our team members, and we prioritize creating and nurturing an environment that supports their development and well-being, as well as encouraging them to be bold and find innovative, new solutions to challenges. These awards validate Boomi’s celebrated company culture as we continue to invest in our people.”
As the pioneer and category leader of cloud-native integration platform as a service (iPaaS), Boomi recently surpassed 20,000 customers , setting an industry record for largest customer base among iPaaS vendors. The company boasts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSIs) in the iPaaS space. Boomi’s low-code platform helps organizations across all industries connect data applications, streamline workflows, and deliver more integrated customer experiences.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years .
The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces .
For a list of open positions on the Boomi team, visit the careers page on the Boomi website.
Additional Resources
- Explore the Boomiverse Community
- Follow Boomi on Twitter , LinkedIn , Facebook , and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com
.
About Comparably
Comparably
is a leading workplace culture and corporate brand reputation platform with over 15 million anonymous employee ratings on 70,000 companies. With the most comprehensive data on large and SMB organizations in nearly 20 different workplace categories – based on gender, ethnicity, age, experience, industry, location, education – it is one of the most used SaaS platforms for employer branding and a trusted third party site for workplace culture and compensation. For more information on Comparably’s studies and annual Best Places to Work Awards, visit Comparably News
.
About Comparably Awards
Comparably Awards
is an annual series highlighting the best companies and CEOs in 16 different workplace culture categories throughout the year. Since launching in late 2017, the awards have always been based solely on sentiment feedback provided by current employees who anonymously rated their employers on Comparably.com during a 12- month look-back period. Employees can answer structured questions (in yes/no, true/false, 1-10 scale, and multiple choice formats) spanning 16 different workplace topics. Each answer is then given a numerical score and compared to companies of similar size. The final data set of winners are compiled from over 15 million ratings across 70,000 companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005282/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom